LY2951742 + Celecoxib

Phase 2Terminated
0 watching 0 views this week Active
52
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Osteoarthritis, Knee

Conditions

Osteoarthritis, Knee

Trial Timeline

Jul 1, 2014 → Jun 1, 2015

About LY2951742 + Celecoxib

LY2951742 + Celecoxib is a phase 2 stage product being developed by Eli Lilly for Osteoarthritis, Knee. The current trial status is terminated. This product is registered under clinical trial identifier NCT02192190. Target conditions include Osteoarthritis, Knee.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT02192190Phase 2Terminated

Competing Products

20 competing products in Osteoarthritis, Knee

See all competitors
ProductCompanyStageHype Score
Duloxetine + PlaceboEli LillyPhase 3
77
LY2828360 + PlaceboEli LillyPhase 2
52
Investigational Medical Product (IMP) administered in parent studyEli LillyPhase 3
77
Duloxetine + Sugar pillEli LillyApproved
85
UBX0101 or placeboUnity BiotechnologyPre-clinical
15
UBX0101Unity BiotechnologyPhase 1
25
UBX0101Unity BiotechnologyPhase 2
44
UBX0101Unity BiotechnologyPhase 1
25
YH23537 + Celecoxib + YH23537 placeboYuhanPhase 2
52
Sodium hyaluronate + placebo injectionDaiichi SankyoPhase 3
77
ASP7962 + Naproxen + PlaceboAstellas PharmaPhase 2
52
Capsaicin Topical SolutionAstellas PharmaApproved
85
CGS-200-1 + CGS-200-5 + CGS-200 VehicleAstellas PharmaPhase 2
52
MM-II dose I + MM-II dose II + MM-II dose III + Placebo + Placebo + PlaceboSun PharmaceuticalPhase 2
52
Duloxetine + PlaceboShionogiPhase 3
77
DuloxetineShionogiPhase 3
77
ONO-4474 Part A1 + Placebo Part A1 + ONO-4474 Part A2 + Placebo Part A2 + ONO-4474 Part B + Placebo Part B + ONO-4474 Part C + Placebo Part C + ONO-4474 Part D + Placebo Part DOno PharmaceuticalPhase 1
33
ONO-4474 + Placebo matching ONO-4474Ono PharmaceuticalPhase 2
52
Duloxetine + PlaceboEli LillyPhase 3
77
LY3556050 + PlaceboEli LillyPhase 2
52